{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Active+dose&page=2", "query": { "intervention": "Single Active dose", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Single+Active+dose&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-15T04:39:59.658Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00074698", "title": "Safety and Tolerability Study of FG-3019 in Participants With Idiopathic Pulmonary Fibrosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Idiopathic Pulmonary Fibrosis" ], "interventions": [ { "name": "FG-3019", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kyntra Bio", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "21 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "21 Years to 80 Years" }, "enrollment_count": 21, "start_date": "2003-12-08", "completion_date": "2004-05", "has_results": false, "last_update_posted_date": "2023-07-12", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 4, "location_summary": "Denver, Colorado • Ann Arbor, Michigan • Dallas, Texas + 1 more", "locations": [ { "city": "Denver", "state": "Colorado" }, { "city": "Ann Arbor", "state": "Michigan" }, { "city": "Dallas", "state": "Texas" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT00074698" }, { "nct_id": "NCT00795132", "title": "Hematopoietic Cell Transplantation for Pediatric Patients With Hematologic Malignancies", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Leukaemia", "Chronic Disease", "Leukemia", "Myelodysplasia", "Lymphoma" ], "interventions": [ { "name": "Busulfan", "type": "DRUG" }, { "name": "Anti-Thymocyte Globulin", "type": "DRUG" }, { "name": "Fludarabine", "type": "DRUG" }, { "name": "Cyclosporine", "type": "DRUG" }, { "name": "Mycophenolate mofetil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "University of Utah", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "21 Years", "sex": "ALL", "summary": "Up to 21 Years" }, "enrollment_count": 47, "start_date": "2004-04", "completion_date": "2009-07", "has_results": true, "last_update_posted_date": "2013-07-30", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00795132" }, { "nct_id": "NCT02257567", "title": "A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Bendamustine", "type": "DRUG" }, { "name": "Obinutuzumab", "type": "DRUG" }, { "name": "Polatuzumab vedotin (Liquid)", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Polatuzumab vedotin (Lyophilized)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 331, "start_date": "2014-10-15", "completion_date": "2021-10-21", "has_results": true, "last_update_posted_date": "2022-11-14", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 16, "location_summary": "Birmingham, Alabama • Huntsville, Alabama • Duarte, California + 13 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Huntsville", "state": "Alabama" }, { "city": "Duarte", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Jacksonville", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT02257567" }, { "nct_id": "NCT07285057", "title": "Diagnostic Utility of rhPSMA-7.3 (18F) PET/CT in Men With Prostate Cancer on Active Surveillance", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Prostatic Neoplasms", "Prostate Cancer", "Prostate Adenocarcinoma" ], "interventions": [ { "name": "rhPSMA-7.3 (18F) PET/CT Imaging (Flotufolastat F18, POSLUMA®)", "type": "RADIATION" }, { "name": "Flotufolastat F18", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "Icahn School of Medicine at Mount Sinai", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 120, "start_date": "2026-02-10", "completion_date": "2027-05-01", "has_results": false, "last_update_posted_date": "2026-02-23", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT07285057" }, { "nct_id": "NCT03712228", "title": "A Study to Investigate CSL312 in Subjects With Hereditary Angioedema (HAE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hereditary Angioedema" ], "interventions": [ { "name": "Factor XIIa antagonist monoclonal antibody", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "CSL Behring", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 44, "start_date": "2018-10-29", "completion_date": "2021-10-15", "has_results": true, "last_update_posted_date": "2022-11-08", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 7, "location_summary": "Orange, California • Walnut Creek, California • Centennial, Colorado + 4 more", "locations": [ { "city": "Orange", "state": "California" }, { "city": "Walnut Creek", "state": "California" }, { "city": "Centennial", "state": "Colorado" }, { "city": "Chevy Chase", "state": "Maryland" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03712228" }, { "nct_id": "NCT03560934", "title": "Tetrahydrocannabinol (THC) and Sleep", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "EARLY_PHASE1" ], "conditions": [ "Sleep", "THC", "Marijuana", "Cannabis" ], "interventions": [ { "name": "Dronabinol", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Oregon Health and Science University", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "21 Years", "maximum_age": "34 Years", "sex": "ALL", "summary": "21 Years to 34 Years" }, "enrollment_count": 18, "start_date": "2018-09-01", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2026-02-05", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 1, "location_summary": "Portland, Oregon", "locations": [ { "city": "Portland", "state": "Oregon" } ], "official_url": "https://clinicaltrials.gov/study/NCT03560934" }, { "nct_id": "NCT03351608", "title": "Efficacy, Safety, and Pharmacokinetics of Sugammadex for Reversal of Neuromuscular Blockade (NMB) in Pediatric Participants (MK-8616-089)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Neuromuscular Blockade" ], "interventions": [ { "name": "Sugammadex 2 mg/kg", "type": "DRUG" }, { "name": "Sugammadex 4 mg/kg", "type": "DRUG" }, { "name": "Neostigmine + Glycopyrrolate", "type": "DRUG" }, { "name": "Neostigmine + Atropine", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merck Sharp & Dohme LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "16 Years", "sex": "ALL", "summary": "2 Years to 16 Years" }, "enrollment_count": 288, "start_date": "2018-02-12", "completion_date": "2020-01-28", "has_results": true, "last_update_posted_date": "2021-02-05", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 11, "location_summary": "Los Angeles, California • Palo Alto, California • San Diego, California + 8 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT03351608" }, { "nct_id": "NCT02002884", "title": "Dose-response Study of Efficacy and Safety of Botulinum Toxin Type A to Treat Spasticity of the Arm(s) or of Arm(s) and Leg(s) in Cerebral Palsy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cerebral Palsy", "Spasticity" ], "interventions": [ { "name": "IncobotulinumtoxinA (8 Units per kg body weight)", "type": "DRUG" }, { "name": "IncobotulinumtoxinA (6 Units per kg body weight)", "type": "DRUG" }, { "name": "IncobotulinumtoxinA (2 Units per kg body weight)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Merz Pharmaceuticals GmbH", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "17 Years", "sex": "ALL", "summary": "2 Years to 17 Years" }, "enrollment_count": 351, "start_date": "2014-03-28", "completion_date": "2018-08-28", "has_results": true, "last_update_posted_date": "2021-08-05", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 6, "location_summary": "Gulf Breeze, Florida • Loxahatchee Groves, Florida • Savannah, Georgia + 3 more", "locations": [ { "city": "Gulf Breeze", "state": "Florida" }, { "city": "Loxahatchee Groves", "state": "Florida" }, { "city": "Savannah", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Royal Oak", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT02002884" }, { "nct_id": "NCT00622635", "title": "A Crossover Study to Determine the 24 Hour Lung Function Profile of Indacaterol in Patients With Moderate-to-severe Chronic Obstructive Pulmonary Disease (COPD)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Indacaterol 300 μg", "type": "DRUG" }, { "name": "Placebo to indacaterol", "type": "DRUG" }, { "name": "Salmeterol 50 μg", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "40 Years", "maximum_age": null, "sex": "ALL", "summary": "40 Years and older" }, "enrollment_count": 68, "start_date": "2008-01", "completion_date": "2008-07", "has_results": true, "last_update_posted_date": "2011-08-18", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 7, "location_summary": "Normal, Illinois • Shawnee Mission, Kansas • Lafayette, Louisiana + 4 more", "locations": [ { "city": "Normal", "state": "Illinois" }, { "city": "Shawnee Mission", "state": "Kansas" }, { "city": "Lafayette", "state": "Louisiana" }, { "city": "Charlotte", "state": "North Carolina" }, { "city": "Raleigh", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT00622635" }, { "nct_id": "NCT02927210", "title": "Injectable DMAU for Male Contraception in Healthy Male Volunteers (CCN015)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Men", "Male Contraception" ], "interventions": [ { "name": "Dimethandrolone Undecanoate", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kimberly Myer", "sponsor_class": "OTHER", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "50 Years", "sex": "MALE", "summary": "18 Years to 50 Years · Male only" }, "enrollment_count": 106, "start_date": "2017-02-15", "completion_date": "2025-04-29", "has_results": false, "last_update_posted_date": "2025-10-31", "last_synced_at": "2026-09-15T04:39:59.658Z", "location_count": 2, "location_summary": "Torrance, California • Seattle, Washington", "locations": [ { "city": "Torrance", "state": "California" }, { "city": "Seattle", "state": "Washington" } ], "official_url": "https://clinicaltrials.gov/study/NCT02927210" } ] }